Study Reveals Type 2 Diabetes Accelerates Chronic Disease Risks

A recent study has uncovered that type 2 diabetes (T2D) significantly contributes to the onset of co-morbidities such as heart failure and chronic kidney disease, particularly in the early stages of the disease. Researchers from Denmark investigated this connection among **502,368** participants in the UK Biobank, revealing that T2D plays a critical role in the accumulation of chronic diseases.

According to forecasts published in **The Lancet** in 2021, T2D is projected to affect an estimated **1.3 billion** people globally by **2050**. Despite advancements in obesity treatments, unhealthy dietary habits and increasingly sedentary lifestyles continue to elevate the risk of diabetes. This study highlights the urgency of understanding how quickly individuals with T2D develop additional chronic conditions and how this progression varies with age.

Rapid Disease Progression in Individuals with T2D

Lead author, **Dr. Jie Zhang**, from the Steno Diabetes Center Aarhus, emphasized that those with T2D exhibited faster progression to further health complications compared to their non-diabetic counterparts. This acceleration was consistent across all age groups, but notably more significant among middle-aged adults.

“The most important message from our findings is that, among individuals with the same number of chronic conditions, those with T2D experience a faster progression to additional conditions, compared to those without T2D,” Dr. Zhang stated. The average age of participants at the start of the study was **58 years**, with approximately **46 percent** being men.

Over an average follow-up period of **15 years**, the researchers monitored health outcomes, noting that **47,725** participants (or **9.5 percent**) were diagnosed with T2D. They assessed how many additional chronic conditions each participant developed from a pool of **80 long-term chronic diseases**.

Utilizing multistate models, the researchers calculated transition rates between groups with equivalent total disease counts. For instance, individuals with T2D and one additional chronic condition progressed to a third condition at a rate of **5.7 percent** per year, while those with two non-T2D chronic conditions progressed at **3.5 percent** per year. This indicates that individuals with T2D face a **60 percent** higher risk of being diagnosed with a new disease compared to those without the condition.

Age-Related Differences in Disease Accumulation

The study also revealed that younger participants with T2D, specifically those aged **40-55 years**, demonstrated a quicker accumulation of chronic diseases than older individuals. Dr. Zhang noted, “This finding underscores the need for early intervention in midlife to slow multimorbidity progression.”

The researchers acknowledged limitations in their study, including the assessment of risk factors like socioeconomic status, smoking, and diet, which were only evaluated at the study’s onset. This approach did not account for changes occurring during the follow-up. Additionally, as those with T2D undergo more frequent medical monitoring, there may be a detection bias, allowing for earlier identification of chronic conditions.

The authors also pointed out that findings may not be generalizable to the wider population, as participants in the UK Biobank are typically healthier and more educated than average.

This research was presented at the **European Association for the Study of Diabetes (EASD)** annual meeting in **September 2023**. It comes in light of the **World Health Organization (WHO)** recently adding GLP-1 therapies, including **liraglutide**, **semaglutide**, and **tirzepatide**, to its Essential Medicines List for high-risk T2D groups. In December, the WHO released its inaugural guidelines on using these therapies for treating obesity as a chronic disease.

“Obesity is a major global health challenge that WHO is committed to addressing by supporting countries and people to control it effectively and equitably,” stated **Dr. Tedros Adhanom Ghebreyesus**, WHO Director-General. “While medication alone won’t solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms.”

This study sheds light on the critical relationship between T2D and chronic diseases, reinforcing the need for targeted care strategies and early interventions. As the global prevalence of diabetes continues to rise, understanding and addressing its implications becomes increasingly vital for public health.